Pregled bibliografske jedinice broj: 399972
Enzyme replacement therapy in three patients with MPS II
Enzyme replacement therapy in three patients with MPS II // Paediatria Croatica. Supplement 2 / Barišić, Ingeborg (ur.).
Zagreb, 2009. str. 48-48 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 399972 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Enzyme replacement therapy in three patients with MPS II
Autori
Petković, Giorgie ; Barišić, Ingeborg
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Paediatria Croatica. Supplement 2
/ Barišić, Ingeborg - Zagreb, 2009, 48-48
Skup
8th Balkan Meeting on Human Genetics
Mjesto i datum
Cavtat, Hrvatska, 14.05.2009. - 17.05.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
MPS II
Sažetak
Mucopolysaccharidosis type II (MPS II) is a rare lysosomal storage disorder due to the deficiency of the lysosome enzyme iduronate sulfatase (IDS). The enzymatic defect leads to the accumulation of dermatan and heparan sulfate in lysosomes causing progressive dysfunction of many tissues and organs. Enzyme replacement therapy (ERT) is now available with idursulfase. Aim: to present our experience with ERT treatment in three patients with MPS II. Patients/Methods: The diagnosis of MPS II was made based on clinical criteria, abnormal urinary glycosaminoglycan (GAG) excretion, deficient serum and/or fibroblast IDS activity, and molecular testing. Two patients had severe form of disease and one patient was mildly affected. After one year of therapy with idursulfase (Elaprase) in two patients with advanced form of MPS II we found no progression of the disease, with stationary findings in stamina, cardiologic status and liver size. Urinary GAG levels returned to nearly normal levels. One of the two patients, who has epilepsy, showed a marked decrease in the frequency of seizure attacks. The patient with a mild form of MPS II, showed after 6 months of treatment increase in stamina, pulmonary function tests, range of motion, and decrease in liver size. Conclusion: ERT treatment prevented the progression of the disorder in two patients with advanced form of disease and considerably improved the condition of the mildly affected patient. The therapy was well tolerated and without serious side effects.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
072-1083107-0365 - Istraživanje epidemiologijskih i genetičkih osnova prirođenih mana (Barišić, Ingeborg, MZOS ) ( CroRIS)
Ustanove:
Klinika za dječje bolesti Medicinskog fakulteta
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus